Results 121 to 130 of about 387,352 (250)

Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis). [PDF]

Front Immunol, 2023
Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Megna M, Mercuri SR, Travaglini M, Costanzo A, Narcisi A.   +20 more
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far? [PDF]

J Inflamm Res
Megna M, D'Agostino M, Feo F, Ventura V, Tommasino N, Potestio L.   +5 more
europepmc   +1 more source

TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors. [PDF]

J Psoriasis Psoriatic Arthritis, 2022
Hong JJ, Hadeler EK, Mosca ML, Brownstone ND, Bhutani T, Liao WJ.   +5 more
europepmc   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

High-Dose, Extended Half-Life IL-23 Inhibitors: the Next Big Step in Psoriasis Care? [PDF]

Dermatol Ther (Heidelb)
Torres T, Blauvelt A.
europepmc   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort study. [PDF]

Ther Adv Musculoskelet Dis
Parisi S, Becciolini A, D'Onofrio B, Lo Gullo A, Addimanda O, Magnani M, Reta M, Andracco R, Mansueto N, Del Medico P, Caccavale R, Paroli M, Larosa M, Bianchi G, Camellino D, Raffeiner B, Nucera V, Ianniello A, Giampietro C, Ometto F, Priora M, Molica Colella AB, Bravi E, Platè I, Arrigoni E, Ravagnani V, Bezzi A, Mascella F, Focherini MC, Fiorenza A, Rovera G, Vitetta R, Scolieri P, Bruzzese V, Volpe A, Bixio R, Marchetta A, Lumetti F, Farina A, Bernardi S, Girelli F, Visalli E, Amato G, De Lucia F, Dal Bosco Y, Foti R, Foti R, Serale F, Cipollone F, Di Penta M, Sabatini E, Celletti E, Franchina V, Colella FM, Ferrero G, Sandri G, Giuggioli D, Ditto MC, Fusaro E, Adorni G, Di Donato E, Santilli D, Lucchini G, Ariani A.   +63 more
europepmc   +1 more source

Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. [PDF]

Am J Clin Dermatol, 2021
Yang K, Oak ASW, Elewski BE.
europepmc   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source